Evidence map›Paper›PMID 39555399›Full record

ArticleiScience2024

Long-term effectiveness of an ultra-rapid rollout vaccination campaign with BNT162b2 on the incidence of SARS-CoV-2 infection.

Lena Tschiderer, Hanna Innerhofer, Lisa Seekircher, Lisa Waltle, Lukas Richter, Janine Kimpel, Cornelia Lass-Flörl, Lukas Forer, Sebastian Schönherr, David A Larsen and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lena TschidererInstitute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Hanna InnerhoferInstitute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Lisa SeekircherInstitute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Lisa WaltleInstitute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Lukas RichterInstitute of Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety, 1220 Vienna, Austria.
Janine KimpelInstitute of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Cornelia Lass-FlörlInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Lukas ForerInstitute of Genetic Epidemiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Sebastian SchönherrInstitute of Genetic Epidemiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
David A LarsenDepartment of Public Health, Syracuse University, Syracuse, NY, USA.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sabine Embacher-AichhornClinical Trial Center, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Herbert TilgDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Günter WeissDepartment of Internal Medicine II, Infectious Diseases, Immunology, Pneumology and Rheumatology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Franz AllerbergerInstitute of Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety, 1220 Vienna, Austria.
Peter WilleitInstitute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2021, an ultra-rapid rollout vaccination campaign in the Schwaz district, Tyrol, Austria, delivered the COVID-19 vaccine BNT162b2 to 66.9% of eligible residents (dose 1: March 11-16, dose 2: April 8-13). Alongside the campaign, we recruited 11,955 residents into the prospective study REDUCE, of whom 3,859 participated in a booster vaccination initiative (November 20-28, 2021). Over a 24-month follow-up, 1,672 participants had incident RT-PCR-confirmed SARS-CoV-2. Compared to other Tyrolean districts, effectiveness in reducing SARS-CoV-2 infection at months 1-9 versus months 10-24 was 81.6% (95% CI 80.0-83.2%; hazard ratio 0.18 [0.17-0.20]) versus 38.2% (35.8-40.6%; 0.62 [0.59-0.64]) among REDUCE participants, and 22.5% (20.5-24.4%; 0.78 [0.76-0.80]) versus 17.0% (16.2-17.8%; 0.83 [0.82-0.84]) in the entire Schwaz district, with substantial variability during follow-up. By March 2023, 61% of Schwaz residents had received booster vaccination versus 55% in other Tyrolean districts. Consequently, vaccinating individuals at high pace effectively reduced SARS-CoV-2 infections and achieved higher vaccination coverage.

Indexed as

Health sciencesPublic healthVirology

Identifiers

PMID39555399
PMCPMC11567098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.